DDInter659 DDInter1729
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Diflunisal {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Levomilnacipran {u} (Compound) causes {v} (Side Effect) Tension
Tension {u} (Side Effect) is caused by {v} (Compound) Sulindac
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Diflunisal {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Sulindac
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Diflunisal {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Sulindac
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Eptifibatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) Sulindac
Eptifibatide {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Eptifibatide {u} may lead to a major life threatening interaction when taken with {v} Ardeparin
Ardeparin {u} (Compound) causes {v} (Side Effect) Malaise
Malaise {u} (Side Effect) is caused by {v} (Compound) Sulindac
Eptifibatide {u} may lead to a major life threatening interaction when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Sulindac (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Sulindac (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Sulindac (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) binds PPARD (Gene) and Treprostinil (Compound) upregulates PPARD (Gene) and PPARD (Gene) is bound by Sulindac (Compound)
Eptifibatide may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Eptifibatide may lead to a major life threatening interaction when taken with Ardeparin and Ardeparin (Compound) causes Malaise (Side Effect) and Malaise (Side Effect) is caused by Sulindac (Compound)
Eptifibatide may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)